Two Republican senators call on CMS to not restrict coverage to amyloid-targeted Alzheimer's drugs
Republican Senators Susan Collins of Maine and Shelley Moore Capito of West Virginia recently sent a letter to CMS, urging the agency to not move forward with its restrictions on covering amyloid-targeted Alzheimer’s drugs ahead of an April 11 deadline for a final national coverage determination.
The senators joined a growing chorus of more than 75 members of Congress and others in industry, like Biogen and BIO, who have insisted that a CMS decision to restrict these new and upcoming Alzheimer’s drugs to only clinical trials would “inappropriately threaten patient access to treatment,” and “thwart advances” in Alzheimer’s R&D.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,300+ biopharma pros reading Endpoints daily — and it's free.